XBIT News and Press, XBiotech Inc. From 12/20/23

American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...

2023-12-15 17:03:39 ET Gainers: Loop Industries ( LOOP ) +6% . Cognyte Software  ( CGNT ) +5% . Generation  ( GBIO ) +5% . Northern Technologies International Corporation ( NTIC ) +5% . Arcturus Therapeutics Holdings ( ARCT ...

Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...

Greif Inc. Class A (GEF) is expected to report $1.3 for Q4 2023 Skandinaviska Enskilda Banken - Class A (SVKEF) is expected to report for Q3 2023 Yellow Corporation (YELLQ) is expected to report for Q3 2023 Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Lakeland Industrie...

Addex Therapeutics Ltd (ADXN) is expected to report $-4 for Q3 2023 Eco Wave Power Global AB (publ) (WAVE) is expected to report for quarter end 2023-09-30 AmeraMex International, Inc. (AMMX) is expected to report for Q3 2023 iClick Interactive Asia Group Limited (ICLK) is expected to...

Tekumo Inc (BCNN) is expected to report for Q3 2023 Diamcor Mining Inc (DMIFF) is expected to report for Q2 2024 American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024 Inspired Entert...

The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...

AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for rh...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Nabriva Therapeutics plc (NBRVF) is expected to report for Q2 2023 JFE Holdings, Inc. (JFEEF) is expected to report for Q1 2024 Superior Gold Inc (SUPGF) is expected to report for Q2 2023 S&W Seed Company (SANW) is expected to report $-0.09 for Q4 2023 Jefferies Financial Grou...